CFO Mark J Rosenblum bought 20,000 shares at $0.80 on 2025-11-20 amid -80.2% 30-day price collapse and -$873.5K quarterly net loss.
Mark J Rosenblum, Exec VP Finance and CFO of Salarius Pharmaceuticals, purchased 20,000 shares at $0.80 on 2025-11-20, increasing his holdings from 177 shares to 20,177 shares. The transaction occurred in an extreme distress environment: the stock has declined -80.2% over the past 30 days and -87.0% over 90 days, currently trading at $0.75 versus a 52-week high of $55.05 (a -98.6% decline). The company reported zero revenue in its latest quarter and a net loss of -$873.5K, with annual revenue down -100.0% year-over-year; the market cap stands at only $4.4M. This insider purchase of a meaningful position by a senior financial executive during a period of extreme price deterioration and documented operational distress suggests a notable commitment at deeply depressed levels, though the lack of profitability and revenue contraction raise structural questions about company viability.